ScionxBio enters worldwide strategic collaboration and licensing pact with Sanofi to develop long-acting xRNA herapeutics: Cambridge, UK Thursday, October 22, 2026, 18:00 Hrs [IST ...
The Strategic alliance advances VL-2511, a first-in-class dual BCMA/CD19 autologous CAR-T therapy for multiple myeloma, ...
Quarterly diluted earnings were 49 cents per share, versus 43 cents a year earlier; nine-month net income fell to $90 million ...
A few days ago, I published a paper database called the 'Somiya Archive 3408' on this note.↓Ivermectin/COVID-19 Related Paper ...
Third-quarter net revenue was $520.1 million, and gross margin rose 90 basis points to 51.7%. Boston Beer expects modest shipment growth in Q4.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results